Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
367-01-006 ISMRM Abstract

Unraveling metabolic alterations associated with lung cancer: A proton NMR based metabolomics study

Primary: Preclinical Animal & in vitro MR - Biomarkers
Secondary: Body - Metabolism
367-01-006 · Fuel and Function: Metabolism in the Body · Monday, 11 May, 8:20 AM–9:15 AM · Digital Posters Row H
Keywords: Metabolism Biomarkers Lung Cancer NMR-based Metabolomics
Accepted
Uma Sharma1, Deepti Upadhyay1, Saumya Jaiswal1, Chandrashekhara S H2, Sunil Kumar3, Prabhat S Malik4
1Department of Nuclear Magnetic Resonance (NMR), All India Institute of Medical Sciences, New Delhi, India
2Department of Radio Diagnosis, IRCH, All India Institute of Medical Sciences, New Delhi, India
3Department of Surgical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India
4Department of Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India
Presenting Author: Durgesh K Dwivedi

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660 [doi]
2. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873 [doi]
3. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429. doi:10.1001/jama.2012.5521 [doi]
4. De Vitto H, Pérez-Valencia J, Radosevich JA. Glutamine at focus: versatile roles in cancer. Tumour Biol. 2016;37(2):1541-1558. doi:10.1007/s13277-015-4671-9. [doi]
5. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11-31. doi:10.1038/nrclinonc.2016.60. [doi]
6. Sousa CM, Biancur DE, Wang X, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536(7617):479-483. doi:10.1038/nature19084. [doi]
7. Zhou Y, Kou J, Li W, Wang Y, Su X, Zhang H. BCAA metabolism in cancer progression and therapy resistance: The balance between fuel and cell signaling. Front Pharmacol. 2025;16:1595176. doi:10.3389/fphar.2025.1595176. [doi]
8. Kuo CC, Wu JY, Wu KK. Cancer-derived extracellular succinate: a driver of cancer metastasis. J Biomed Sci. 2022;29(1):93. doi:10.1186/s12929-022-00878-z. [doi]
9. Sonkar K, Ayyappan V, Tressler CM, et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed. 2019;32(10):e4112. doi:10.1002/nbm.4112. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/367-01-006